508 related articles for article (PubMed ID: 34168976)
1. Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.
Garcia-Fabiani MB; Haase S; Comba A; Carney S; McClellan B; Banerjee K; Alghamri MS; Syed F; Kadiyala P; Nunez FJ; Candolfi M; Asad A; Gonzalez N; Aikins ME; Schwendeman A; Moon JJ; Lowenstein PR; Castro MG
Front Oncol; 2021; 11():631037. PubMed ID: 34168976
[TBL] [Abstract][Full Text] [Related]
2. Glioma: bridging the tumor microenvironment, patient immune profiles and novel personalized immunotherapy.
Mishchenko TA; Turubanova VD; Gorshkova EN; Krysko O; Vedunova MV; Krysko DV
Front Immunol; 2023; 14():1299064. PubMed ID: 38274827
[TBL] [Abstract][Full Text] [Related]
3. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.
Plant-Fox AS; O'Halloran K; Goldman S
Curr Probl Cancer; 2021 Aug; 45(4):100777. PubMed ID: 34303558
[TBL] [Abstract][Full Text] [Related]
4. Exploitation of immune mechanisms in the treatment of central nervous system cancer.
Pollack IF; Okada H; Chambers WH
Semin Pediatr Neurol; 2000 Jun; 7(2):131-43. PubMed ID: 10914414
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development.
Garcia-Fabiani MB; Ventosa M; Comba A; Candolfi M; Nicola Candia AJ; Alghamri MS; Kadiyala P; Carney S; Faisal SM; Schwendeman A; Moon JJ; Scheetz L; Lahann J; Mauser A; Lowenstein PR; Castro MG
Expert Opin Investig Drugs; 2020 Jul; 29(7):659-684. PubMed ID: 32400216
[TBL] [Abstract][Full Text] [Related]
6. Pre-clinical models for evaluating glioma targeted immunotherapies.
Frederico SC; Zhang X; Hu B; Kohanbash G
Front Immunol; 2022; 13():1092399. PubMed ID: 36700223
[TBL] [Abstract][Full Text] [Related]
7. Immune microenvironment of gliomas.
Gieryng A; Pszczolkowska D; Walentynowicz KA; Rajan WD; Kaminska B
Lab Invest; 2017 May; 97(5):498-518. PubMed ID: 28287634
[TBL] [Abstract][Full Text] [Related]
8. Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment.
Franson A; McClellan BL; Varela ML; Comba A; Syed MF; Banerjee K; Zhu Z; Gonzalez N; Candolfi M; Lowenstein P; Castro MG
Front Med (Lausanne); 2022; 9():966458. PubMed ID: 36186781
[TBL] [Abstract][Full Text] [Related]
9. Cell-based immunotherapy against gliomas: from bench to bedside.
Bovenberg MS; Degeling MH; Tannous BA
Mol Ther; 2013 Jul; 21(7):1297-305. PubMed ID: 23648695
[TBL] [Abstract][Full Text] [Related]
10. Hallmarks of the Tumour Microenvironment of Gliomas and Its Interaction with Emerging Immunotherapy Modalities.
Linares CA; Varghese A; Ghose A; Shinde SD; Adeleke S; Sanchez E; Sheriff M; Chargari C; Rassy E; Boussios S
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686020
[TBL] [Abstract][Full Text] [Related]
11. Innovative therapies for malignant brain tumors: the road to a tailored cure.
Giotta Lucifero A; Luzzi S; Brambilla I; Trabatti C; Mosconi M; Savasta S; Foiadelli T
Acta Biomed; 2020 Jun; 91(7-S):5-17. PubMed ID: 32608372
[TBL] [Abstract][Full Text] [Related]
12. Single vs. combination immunotherapeutic strategies for glioma.
Chandran M; Candolfi M; Shah D; Mineharu Y; Yadav VN; Koschmann C; Asad AS; Lowenstein PR; Castro MG
Expert Opin Biol Ther; 2017 May; 17(5):543-554. PubMed ID: 28286975
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for Recurrent Glioma-From Bench to Bedside.
Pu Y; Zhou G; Zhao K; Chen Y; Shen S
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444531
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.
Zeng J; Li X; Sander M; Zhang H; Yan G; Lin Y
Front Immunol; 2021; 12():721830. PubMed ID: 34675919
[TBL] [Abstract][Full Text] [Related]
15. Research Progress in Immunotherapy of Gliomas.
Duan ZH; Wei ZL
J Integr Neurosci; 2023 Aug; 22(5):118. PubMed ID: 37735122
[TBL] [Abstract][Full Text] [Related]
16. Deciphering immune microenvironment and cell evasion mechanisms in human gliomas.
Rafii S; Kandoussi S; Ghouzlani A; Naji O; Reddy KP; Ullah Sadiqi R; Badou A
Front Oncol; 2023; 13():1135430. PubMed ID: 37274252
[TBL] [Abstract][Full Text] [Related]
17. Single-Cell Omics in Dissecting Immune Microenvironment of Malignant Gliomas-Challenges and Perspectives.
Kaminska B; Ochocka N; Segit P
Cells; 2021 Aug; 10(9):. PubMed ID: 34571910
[TBL] [Abstract][Full Text] [Related]
18. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
19. Rediscovering Potential Molecular Targets for Glioma Therapy Through the Analysis of the Cell of Origin, Microenvironment and Metabolism.
Guo X; Wang T; Huang G; Li R; Da Costa C; Li H; Lv S; Li N
Curr Cancer Drug Targets; 2021; 21(7):558-574. PubMed ID: 33949933
[TBL] [Abstract][Full Text] [Related]
20. Prognosis prediction and tumor immune microenvironment characterization based on tryptophan metabolism-related genes signature in brain glioma.
Zhang S; Chen S; Wang Z; Li J; Yuan Y; Feng W; Li W; Chen M; Liu Y
Front Pharmacol; 2022; 13():1061597. PubMed ID: 36386216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
